Clinical trial · Interventional
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
Phase I Study of KN026 in HER2 Expressing Breast Cancer, Astric/Gastroesophageal Junction Cancer and Other Locally Advanced/Metastatic Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation. There are 3 proposed dose levels which are 10, 15, and 20 mg/kg, but dosing interval may be adjusted during the study (such as QW, OR Q2W, OR Q3W) based on emerging data from this trial and/or from phase 1 trial of KN026 in other country. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or if MTD is not found, dose escalation will continue until the MAD of 20 mg / kg is reached.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Gastric/Gastroesophageal Junction Cancer | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| KN026 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- KN026
- description
- Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
- interventionNames
- Drug: KN026
Primary outcomes (1)
- measure
- The proportion of patients experiencing dose limiting toxicities
- timeFrame
- From screening to up to 28 days
Secondary outcomes (6)
- measure
- Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest
- timeFrame
- From screening to up to 196 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female subject \>= 18 years * Histologically/cytologically confirmed, locally advanced unresectable or metastatic breast cancer or gastric cancer. * ECOG score 0 or 1 * Life expectancy \>3 months * According to the definition of RECIST1.1, the patient has at least one measurable lesion * Adequate organ function prior to start treatment with KN026 * Able to understand, voluntarily participate and willing to sign the ICF * Subjects (women of child-bearing potential and males with fertile female partner) must be willing to use viable contraception method. Exclusion Criteria: * Accepted any other anti-tumor drug therapies within 4 weeks before fist dose * Accepted radiotherapy within 4 weeks before enrollment * An anthracyclines antibiotic treatment was received exceeding 300 mg/m² within 90 days before first KN026 dosing, or other equivalent dose antharcyclines * Subjects are eligible with clinically controlled and stable neurologic function \>= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible * Pregnant or nursing females；or intend pregnancy within this study period or within 6 monthes after the end of this study * History of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation * Severe chronic and active infection, need to system antibiosis/antiviral treatment * Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage
References
Publications (0)
Data not yet available